OPKO and Entera Bio join forces to develop oral dual agonist for health conditions

From Nasdaq, Inc.: 2025-03-17 19:07:01

OPKO Health and Entera Bio have teamed up to develop an oral dual agonist GLP-1/glucagon peptide for various health conditions. The once-daily tablet combines OPKO’s OPK-88006 with Entera’s N-Tab technology. Preclinical data has shown promise, and an IND application is expected to be filed with the FDA soon.

The collaboration agreement gives OPKO 60% ownership and Entera 40%, with shared development costs. OPKO also bought 3.69 million Entera shares at $2.17 each to fund Phase 1. If Entera exits after Phase 1, its stake drops to 15%, with OPKO taking 85% ownership and full funding responsibility.

On Monday, OPKO closed at $1.81, up 4.02%, and is trading at $1.85 after hours on the Nasdaq Global Select Market.



Read more at Nasdaq, Inc.: OPKO & Entera Bio To Develop First Oral GLP-1/Glucagon Dual Agonist